LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $46.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $24K to $185K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $46.9M and bought $0 of ABT stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Ford, Robert B (Chairman And CEO), who sold $46.2M. The latest filing was on Sep 3, 2026.
Rep. Gilbert Cisneros (D) bought $1K to $15K on Sep 18, 2026, disclosed 24 days later. Rep. Richard Dean McCormick (R) sold $1K to $15K on Jul 30, 2026, disclosed 15 days later. Rep. Mike Kelly (R) sold $1K to $15K on Jul 17, 2026, disclosed 26 days later. Rep. Richard W. Allen (R) sold $15K to $50K on Jul 14, 2026, disclosed 35 days later. In total, 7 members disclosed 10 ABT trades with trade dates in the last 180 days, filed a median 25 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders are trading both ways.
Buys/Adds (2)
Citadel
$583.4M
added
AQR
$219.5M
added
Sells/Trims (1)
D.E. Shaw
$409.8M
trimmed
Sells (3)
Mccoy John A. Jr.
$3K
sold
Ford Robert B
$46.2M
sold
Morrone Louis H.
$643K
sold
Buys (1)
No tracked top-trader positions in ABT right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 16, 2026
Financial period
Q2 2026
Earnings per share
$1.28 expected
Revenue
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 16, 2026 | $1.31 / $1.28Alpha Vantage | +2.34% beat | $12.59B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 16, 2026 | $1.15 / $1.15Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Dec 31, 2025 | Jan 22, 2026 | $1.50 / $1.49Alpha Vantage | +0.67% in line | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 15, 2025 | $1.30 / $1.30Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 17, 2025 | $1.26 / $1.26Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 16, 2025 | $1.09 / $1.07Alpha Vantage | +1.87% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 22, 2025 | $1.34 / $1.34Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 16, 2024 | $1.21 / $1.20Alpha Vantage | +0.83% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$1.31 to $1.44
Revenue expected
24 analysts
Last 30 days
Analysts raising estimates
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.14B | $11.37B | $11.46B | $11.16B |
| Cost of what it sold | $4.85B | $5.03B | $4.92B | $4.88B |
| Gross profit | $6.29B | $6.34B | $6.54B | $6.28B |
| What it spent | ||||
| Research and development | $732.0M | $785.0M | $735.0M | $756.0M |
| Sales and admin | $3.09B | $3.05B | $3.13B | $3.74B |
| Other operating costs | $414.0M | $472.0M | $422.0M | -$55.0M |
| Total operating expenses | $4.24B | $4.31B | $4.29B | $4.44B |
| What was left | ||||
| Operating profit | $2.05B | $2.06B | $2.25B | $1.84B |
| Interest on debt | $121.0M | $44.0M | $120.0M | $174.0M |
| Profit before tax | $2.15B | $2.18B | $2.36B | $1.45B |
| Tax | $371.0M | $536.0M | $582.0M | $372.0M |
| Net profit | $1.78B | $1.64B | $1.78B | $1.08B |
| EBITDA | $3.05B | $3.09B | $3.19B | $2.25B |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Rothschild raises target for Abbott Laboratories stock to USD 127.00
BullishOct 15Senseonics Bets a No-Money Deal With Beta Bionics Can Pull It Out of a Niche
NeutralOct 15Abbott Laboratories To Go Ex-Dividend On October 15th, 2026 With 0.63 USD Dividend Per Share
Leans bullishOct 14Abbott Laboratories stock may move 4.7% on earnings release
NeutralOct 14Heart Valve Lawsuit Alleges Abbott Trifecta GT Failed Years Earlier Than Expected
BearishOct 14Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins?
Leans bullishOct 14Rothschild Redburn raises target for Abbott Laboratories stock to USD 127
BullishOct 14Abbott Laboratories schedules third-quarter results for October 21; stock pre-market at EUR 91.62
Leans bullishOct 1430 macro signals shaping ABT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results